CIK 0001178670
- Large accelerated filer
ALNYLAM PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- ALNY
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 770602661
- Phone
- +1 617-551-8200
- Business address
- 675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, 02142
- Former names
- ALNYLAM PHARMACEUTICALS INC
- Open-market buys, last 90 days
- $543,126
- in 2 filings
- Open-market sales, last 90 days
- $398,855
- in 1 filing
Net +$144,271. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-02-20 | MARAGANORE JOHN Chief Executive Officer | Exercise or conversion | +34,765 | $9.14 | $318K | 224,758 |
| 2020-02-20 | MARAGANORE JOHN Chief Executive Officer | Sale | −2,672 | $128.62 | $344K | 222,086 |
| 2020-02-20 | MARAGANORE JOHN Chief Executive Officer | Sale | −1,586 | $129.33 | $205K | 220,500 |
| 2020-02-20 | MARAGANORE JOHN Chief Executive Officer | Sale | −5,053 | $131.07 | $662K | 215,447 |
| 2020-02-20 | MARAGANORE JOHN Chief Executive Officer | Sale | −6,887 | $131.61 | $906K | 208,560 |
| 2020-02-20 | MARAGANORE JOHN Chief Executive Officer | Sale | −18,065 | $132.81 | $2.4M | 190,495 |
| 2020-02-20 | MARAGANORE JOHN Chief Executive Officer | Sale | −502 | $133.42 | $67K | 189,993 |
| 2020-02-20 | MARAGANORE JOHN Chief Executive Officer | Exercise or conversion · Stock Option (right to buy) | −34,765 | 104,295 | ||
| 2020-02-12 | SHARP PHILLIP A Director | Exercise or conversion | +15,000 | $15.82 | $237K | 250,633 |
| 2020-02-12 | SHARP PHILLIP A Director | Exercise or conversion | +15,000 | $9.14 | $137K | 265,633 |
| 2020-02-12 | SHARP PHILLIP A Director | Sale | −30,000 | $130.00 | $3.9M | 235,633 |
| 2020-02-12 | SHARP PHILLIP A Director | Exercise or conversion · Non-Qualified Stock Option (right to buy) | −15,000 | 0 | ||
| 2020-02-12 | SHARP PHILLIP A Director | Exercise or conversion · Stock Option (right to buy) | −15,000 | 0 | ||
| 2020-02-10 | KEATING LAURIE EVP, Chief Legal Officer | Exercise or conversion | +10,000 | $77.40 | $774K | 22,258 |
| 2020-02-10 | KEATING LAURIE EVP, Chief Legal Officer | Sale | −10,000 | $129.00 | $1.3M | 12,258 |
| 2020-02-10 | KEATING LAURIE EVP, Chief Legal Officer | Exercise or conversion · Stock Option (right to buy) | −10,000 | 52,000 | ||
| 2020-01-27 | KEATING LAURIE EVP, Chief Legal Officer | Exercise or conversion | +3,663 | $77.40 | $284K | 12,258 |
| 2020-01-03 | Poulton Jeffrey V. Chief Financial Officer | Other acquisition | +19 | 19 | ||
| 2019-10-10 | Poulton Jeffrey V. Chief Financial Officer | Other acquisition | +38 | 38 | ||
| 2017-05-31 | Sanofi 10% owner | Purchase | +297,501 | $71.87 | $21.4M | 10,554,134 |
Page 79 of 80 · 1,590 trades